MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
convertible debt
$478,000
Proceeds from short term
loans, others
$150,000
Net cash provided by
financing activities
$628,000
Net increase
(decrease) in cash
$320,978
Canceled cashflow
$307,022
Change in fair value of
derivative
-$392,058
Stock based
compensation
$183,742
Accounts payable and
accrued expenses
$155,661
Amortization of debt discount
and deferred...
$54,478
Prepaid expenses and
other current assets
-$20,894
Accounts payable to
related party
$514
Net cash used in
operating activities
-$307,022
Canceled cashflow
$807,347
Net loss before
non-controlling interests
-$1,114,369
Back
Back
Cash Flow
source: myfinsight.com
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)